Compare Estee Lauder Companies Inc (EL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Pfizer Inc — how do they compare? Estee Lauder Companies Inc trades at $98.23 (market cap $34.17B), while Pfizer Inc trades at $28.24 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 4.6× Estee Lauder Companies Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and Pfizer Inc for 158 Days on average.
| EL | PFE | |
|---|---|---|
Market Cap | $34.17B | $158.56B |
Volume | 3,921,497 | 44,138,282 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $29.02 |
52-Week Low | $67.23 | $23.67 |
Typical Hold Time | 122 Days | 158 Days |
Enterprise Value | $39.92B | $210.06B |
Dividend Yield | 1.48% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $97.81, up 3.56% with recent earnings beats but faces fundamental challenges including a net loss of $1.13B in 2025. The stock shows neutral technical signals with support at $90 and resistance at $98, while analyst consensus remains positive with a $103 price target. Recent developments include AI partnerships and leadership changes aimed at revitalizing the brand.
The outlook hinges on margin recovery and revenue stabilization, with 2026 projections showing a return to profitability. Key risks include competitive pressures and execution of turnaround strategy, but institutional sentiment remains cautiously optimistic given the company's strong brand portfolio and digital initiatives.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
